510(k) — NDA/BLA submission
Q1 2027
Advancement toward a planned 510(k) submission to the FDA, currently anticipated in the first quarter of calendar 2027Source filing
CNXU biotech catalysts & pipeline
CONEXEU SCIENCES INC · Data as of 2026-10-25
Upcoming catalysts
CXU™ — NDA/BLA submission
Q1 2027
• Advancement toward a planned 510(k) submission to the FDA, currently anticipated in the first quarter of calendar 2027Source filing
Ten Minute Tissue™ — NDA/BLA submission
Q1 2027
Conexeu Sciences Inc. Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company's planned FDA 510(k) submission in the first quarter of 2027Source filing